stars 1 stars 2 stars 3

Ractigen Therapeutics is a clinical-stage biotechnology company pioneering a new class of genetic medicines: small activating RNA (saRNA). While traditional oligonucleotide therapies focus on silencing genes, Ractigen’s platform is built on the paradigm-shifting discovery of RNA activation (RNAa). Founded in 2016 by the leading pioneers of the RNAa field, we develop first-in-class therapies that selectively upregulate and restore the expression of therapeutic genes in diseased cells. By pairing advanced saRNA design with proprietary targeted delivery platforms, we are advancing a diverse pipeline of candidate medicines across areas of high unmet need, including neurological disorders, oncology, and rare genetic diseases. At Ractigen, team members join a collaborative, mission-driven environment that emphasizes scientific excellence, bold innovation, and a relentless focus on delivering life-changing impact for patients.

Ractigen Therapeutics Questions

The Ractigen Therapeutics annual revenue was $4 million in 2026.

Long-Cheng Li is the Co-founder, President and CEO of Ractigen Therapeutics.

12 people are employed at Ractigen Therapeutics.

Ractigen Therapeutics is based in Suzhou, Jiangsu.

The NAICS codes for Ractigen Therapeutics are [32541, 325, 3254, 32].

The SIC codes for Ractigen Therapeutics are [28, 283].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users